Pharmaceutical Commerce - January/February 2009

Manufacturers have a growing number of service offerings to reach patients with adherence advice

Moving boxes is becoming just one of a growing slate of services from third-party logistics (3PL) providers

Mature product franchises and mixed clinical outcomes have not dissuaded pharma companies from expending marketing resources for cardiovascular disease treatment

Surveys from SDI and Market Strategies International score companies on their promotional practices and business relationships

Expect a flood of product-liability suits in the aftermath of Wyeth vs. Levine

Two prefilled-syringe projects emphasize user friendliness

Optimized dimensionality is the goal of new products from MTS and Cold Chain Technologies

Unified corporate image emphasizes supply chain services

Contract packagers are multiplying their product offerings to meet marketing and patient-safety concerns

BIOPHARMA INDUSTRY

American Recovery and Reinvestment Act allocates $18 billion for HIT

Bipartisan group of senators sponsor a revived drug-importation bill

Although human trials in the U.S. are still a novelty, developers are identifying both sources and protocols for conducting therapy

Regulatory attention has intensified over commercial activities. Here’s what to do to minimize risks and raise compliance levels

The studio model: how film industry practices can boost pharmaceutical creativity

Expect a flood of product-liability suits in the aftermath of Wyeth vs. Levine

While California’s e-pedigree initiative sits on a shelf, actions in Washington and Brussels point to renewed efforts for track-and-trace of pharmaceuticals

Although beset by less-than-friendly federal reimbursement policies, independent pharmacies are maintaining their viability for pharmaceutical delivery

Biopharmaceutical manufacturers turn to a direct-distribution model to leverage opportunities for cost-effective drug delivery and personalized health management services

Alleged mishandling of discarded patient records call the giant retailer’s privacy safeguards into question

The high-tech mecca plans to maintain its status as an economic driver for North Carolina

Nemours plans campus for pediatric treatment and research

Stable economics and growing healthcare concerns make Brazil one of the top emerging markets, with a current growth rate >20%

Multiplying state laws on marketing and distribution disclosures might be pre-empted by new federal legislation

McKesson is a heavy hitter in the category, says Kalorama Information

Higher complexity—and expense—are the reality for most drug research, says Tufts

Higher co-pays, ‘NDC block policies’ and multiple tiers add to drug benefit complexity